Boehringer Ingelheim's empagliflozin gets CDSCO nod for heart failure with preserved ejection fraction Medical Dialogues Bureau19 May 2022 10:49 AM GMTNew Delhi: Boehringer Ingelheim, one of the world's leading, research-driven pharmaceutical companies, has received approval from the Central Drugs...
Setback: AstraZeneca proposal to market, manufacture Olaparib rejected by CDSCO panel Medical Dialogues Team23 April 2022 11:33 AM GMTNew Delhi: In a major setback to AstraZeneca, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has...
Sun Pharma gets CDSCO panel okay for phase 3 trial of Pimavanserin Medical Dialogues Team29 Jan 2022 7:21 AM GMTNew Delhi: Pharmaceutical major, Sun Pharma has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Covishield, Covaxin get regular market approval MD Bureau20 Jan 2022 11:09 AM GMTNew Delhi: India's two main vaccines, Bharat Biotech's Covaxin and Serum Institute of India's Covishield, on Wednesday got the nod for regular market...
CDSCO approves extension of Covaxin shelf life up to 12 months ruchika21 Dec 2021 7:30 AM GMTCovaxin Open Vial is stable at 2 to 8 degrees Celsius for 28 days and not required to be discarded immediately in a day or at the end of immunisation...
CDSCO panel seeks additional data on Covovax from Serum Institute ruchika29 Nov 2021 6:43 AM GMTNew Delhi: An expert panel of India's Central Drug Authority, which recently reviewed Serum Institute's application seeking emergency authorisation of ...
Proud Moment for India: Bharat Biotech Covaxin gets WHO approval for emergency use listing Farhat Nasim6 Nov 2021 9:39 AM GMTBesides demonstrating 77.8 per cent effectiveness against symptomatic COVID, Covaxin has shown 65.2 per cent protection against the new Delta variant.
Govt notifies NIAB as central drugs lab for COVID vaccines ruchika19 Aug 2021 6:30 AM GMTHyderabad: In a move that will speed up the testing and lot release of Covid-19 vaccines, the National Institute of Animal Biotechnology (NIAB),...
Delhi HC seeks Centre reply on PIL against Covaxin trial on 2-18 age group ruchika20 May 2021 4:30 AM GMTKumar, in his plea, has raised an apprehension that the children who would be part of the trial could suffer adverse health or mental effects due to...
Delhi HC reprimands DCGI after portions of CDSCO drug approval process report found missing Farhat Nasim22 Feb 2021 12:54 PM GMTThe court also directed DCGI to file a status report with regard to the steps taken by it to digitize its records, saying 'there is no reason why DCGI ...
No info to CDSCO about specific severe adverse event linked to Covid-19 vaccines: MoS Health Medical Dialogues Bureau6 Feb 2021 12:01 PM GMT'If any vaccine recipient develops symptoms of COVID19, vaccine recipient will be provided a medically recognized standard of care in the government...
Pfizer, SII, Bharat Biotech seek emergency use authorization for COVID vaccines: CDSCO panel to reconvene on Jan 1 Medical Dialogues Bureau31 Dec 2020 9:14 AM GMTNew Delhi: An expert panel in the Central Drugs Standard Control Organisation (CDSCO) that met on Wednesday to consider emergency use authorization...
